File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Epigenetic inactivation of the miR-124-1 in haematological malignancies
  • Basic View
  • Metadata View
  • XML View
TitleEpigenetic inactivation of the miR-124-1 in haematological malignancies
 
AuthorsWong, KY1
So, CC1
Loong, F1
Chung, LP1
Lam, WWL2
Liang, R1
Li, GKH1
Jin, DY1
Chim, CS1
 
Issue Date2011
 
PublisherPublic Library of Science. The Journal's web site is located at http://www.plosone.org/home.action
 
CitationPlos One, 2011, v. 6 n. 4 [How to Cite?]
DOI: http://dx.doi.org/10.1371/journal.pone.0019027
 
AbstractmiR-124-1 is a tumour suppressor microRNA (miR). Epigenetic deregulation of miRs is implicated in carcinogenesis. Promoter DNA methylation and histone modification of miR-124-1 was studied in 5 normal marrow controls, 4 lymphoma, 8 multiple myeloma (MM) cell lines, 230 diagnostic primary samples of acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), MM, and non-Hodgkin's lymphoma (NHL), and 53 MM samples at stable disease or relapse. Promoter of miR-124-1 was unmethylated in normal controls but homozygously methylated in 4 of 4 lymphoma and 4 of 8 myeloma cell lines. Treatment of 5-Aza-2′-deoxycytidine led to miR-124-1 demethylation and re-expression of mature miR-124, which also associated with emergence of euchromatic trimethyl H3K4 and consequent downregulation of CDK6 in myeloma cells harboring homozygous miR-124-1 methylation. In primary samples at diagnosis, miR-124-1 methylation was absent in CML but detected in 2% each of MM at diagnosis and relapse/progression, 5% ALL, 15% AML, 14% CLL and 58.1% of NHL (p&0.001). Amongst lymphoid malignancies, miR-124-1 was preferentially methylated in NHL than MM, CLL or ALL. In primary lymphoma samples, miR-124-1 was preferentially hypermethylated in B- or NK/T-cell lymphomas and associated with reduced miR-124 expression. In conclusion, miR-124-1 was hypermethylated in a tumour-specific manner, with a heterochromatic histone configuration. Hypomethylation led to partial restoration of euchromatic histone code and miR re-expression. Infrequent miR-124-1 methylation detected in diagnostic and relapse MM samples showed an unimportant role in MM pathogenesis, despite frequent methylation found in cell lines. Amongst haematological cancers, miR-124-1 was more frequently hypermethylated in NHL, and hence warrants further study. © 2011 Wong et al.
 
ISSN1932-6203
2012 Impact Factor: 3.73
2012 SCImago Journal Rankings: 1.512
 
DOIhttp://dx.doi.org/10.1371/journal.pone.0019027
 
PubMed Central IDPMC3081325
 
ISI Accession Number IDWOS:000290015800033
Funding AgencyGrant Number
University of Hong Kong200804159005
200811159040
Hong Kong Research Grants Council General Research Fund763409M
Funding Information:

This work was supported by The University of Hong Kong Seed Funding Programme for Basic Research (Code: 200804159005 and 200811159040), and the Hong Kong Research Grants Council General Research Fund (Ref. 763409M) awarded to Dr C.S. Chim. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorWong, KY
 
dc.contributor.authorSo, CC
 
dc.contributor.authorLoong, F
 
dc.contributor.authorChung, LP
 
dc.contributor.authorLam, WWL
 
dc.contributor.authorLiang, R
 
dc.contributor.authorLi, GKH
 
dc.contributor.authorJin, DY
 
dc.contributor.authorChim, CS
 
dc.date.accessioned2011-08-26T14:24:00Z
 
dc.date.available2011-08-26T14:24:00Z
 
dc.date.issued2011
 
dc.description.abstractmiR-124-1 is a tumour suppressor microRNA (miR). Epigenetic deregulation of miRs is implicated in carcinogenesis. Promoter DNA methylation and histone modification of miR-124-1 was studied in 5 normal marrow controls, 4 lymphoma, 8 multiple myeloma (MM) cell lines, 230 diagnostic primary samples of acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), MM, and non-Hodgkin's lymphoma (NHL), and 53 MM samples at stable disease or relapse. Promoter of miR-124-1 was unmethylated in normal controls but homozygously methylated in 4 of 4 lymphoma and 4 of 8 myeloma cell lines. Treatment of 5-Aza-2′-deoxycytidine led to miR-124-1 demethylation and re-expression of mature miR-124, which also associated with emergence of euchromatic trimethyl H3K4 and consequent downregulation of CDK6 in myeloma cells harboring homozygous miR-124-1 methylation. In primary samples at diagnosis, miR-124-1 methylation was absent in CML but detected in 2% each of MM at diagnosis and relapse/progression, 5% ALL, 15% AML, 14% CLL and 58.1% of NHL (p&0.001). Amongst lymphoid malignancies, miR-124-1 was preferentially methylated in NHL than MM, CLL or ALL. In primary lymphoma samples, miR-124-1 was preferentially hypermethylated in B- or NK/T-cell lymphomas and associated with reduced miR-124 expression. In conclusion, miR-124-1 was hypermethylated in a tumour-specific manner, with a heterochromatic histone configuration. Hypomethylation led to partial restoration of euchromatic histone code and miR re-expression. Infrequent miR-124-1 methylation detected in diagnostic and relapse MM samples showed an unimportant role in MM pathogenesis, despite frequent methylation found in cell lines. Amongst haematological cancers, miR-124-1 was more frequently hypermethylated in NHL, and hence warrants further study. © 2011 Wong et al.
 
dc.description.naturepublished_or_final_version
 
dc.identifier.citationPlos One, 2011, v. 6 n. 4 [How to Cite?]
DOI: http://dx.doi.org/10.1371/journal.pone.0019027
 
dc.identifier.citeulike9257474
 
dc.identifier.doihttp://dx.doi.org/10.1371/journal.pone.0019027
 
dc.identifier.eissn1932-6203
 
dc.identifier.epagee19027
 
dc.identifier.hkuros189637
 
dc.identifier.isiWOS:000290015800033
Funding AgencyGrant Number
University of Hong Kong200804159005
200811159040
Hong Kong Research Grants Council General Research Fund763409M
Funding Information:

This work was supported by The University of Hong Kong Seed Funding Programme for Basic Research (Code: 200804159005 and 200811159040), and the Hong Kong Research Grants Council General Research Fund (Ref. 763409M) awarded to Dr C.S. Chim. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

 
dc.identifier.issn1932-6203
2012 Impact Factor: 3.73
2012 SCImago Journal Rankings: 1.512
 
dc.identifier.issue4
 
dc.identifier.pmcidPMC3081325
 
dc.identifier.pmid21544199
 
dc.identifier.scopuseid_2-s2.0-79955526497
 
dc.identifier.spagee19027
 
dc.identifier.urihttp://hdl.handle.net/10722/137369
 
dc.identifier.volume6
 
dc.languageeng
 
dc.publisherPublic Library of Science. The Journal's web site is located at http://www.plosone.org/home.action
 
dc.publisher.placeUnited States
 
dc.relation.ispartofPLoS ONE
 
dc.relation.referencesReferences in Scopus
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subject.meshEpigenesis, Genetic - genetics
 
dc.subject.meshHematologic Neoplasms - genetics
 
dc.subject.meshLeukemia, Lymphocytic, Chronic, B-Cell - genetics
 
dc.subject.meshLymphoma - genetics
 
dc.subject.meshMicroRNAs - genetics
 
dc.titleEpigenetic inactivation of the miR-124-1 in haematological malignancies
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Wong, KY</contributor.author>
<contributor.author>So, CC</contributor.author>
<contributor.author>Loong, F</contributor.author>
<contributor.author>Chung, LP</contributor.author>
<contributor.author>Lam, WWL</contributor.author>
<contributor.author>Liang, R</contributor.author>
<contributor.author>Li, GKH</contributor.author>
<contributor.author>Jin, DY</contributor.author>
<contributor.author>Chim, CS</contributor.author>
<date.accessioned>2011-08-26T14:24:00Z</date.accessioned>
<date.available>2011-08-26T14:24:00Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Plos One, 2011, v. 6 n. 4</identifier.citation>
<identifier.issn>1932-6203</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/137369</identifier.uri>
<description.abstract>miR-124-1 is a tumour suppressor microRNA (miR). Epigenetic deregulation of miRs is implicated in carcinogenesis. Promoter DNA methylation and histone modification of miR-124-1 was studied in 5 normal marrow controls, 4 lymphoma, 8 multiple myeloma (MM) cell lines, 230 diagnostic primary samples of acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), MM, and non-Hodgkin&apos;s lymphoma (NHL), and 53 MM samples at stable disease or relapse. Promoter of miR-124-1 was unmethylated in normal controls but homozygously methylated in 4 of 4 lymphoma and 4 of 8 myeloma cell lines. Treatment of 5-Aza-2&#8242;-deoxycytidine led to miR-124-1 demethylation and re-expression of mature miR-124, which also associated with emergence of euchromatic trimethyl H3K4 and consequent downregulation of CDK6 in myeloma cells harboring homozygous miR-124-1 methylation. In primary samples at diagnosis, miR-124-1 methylation was absent in CML but detected in 2% each of MM at diagnosis and relapse/progression, 5% ALL, 15% AML, 14% CLL and 58.1% of NHL (p&amp;0.001). Amongst lymphoid malignancies, miR-124-1 was preferentially methylated in NHL than MM, CLL or ALL. In primary lymphoma samples, miR-124-1 was preferentially hypermethylated in B- or NK/T-cell lymphomas and associated with reduced miR-124 expression. In conclusion, miR-124-1 was hypermethylated in a tumour-specific manner, with a heterochromatic histone configuration. Hypomethylation led to partial restoration of euchromatic histone code and miR re-expression. Infrequent miR-124-1 methylation detected in diagnostic and relapse MM samples showed an unimportant role in MM pathogenesis, despite frequent methylation found in cell lines. Amongst haematological cancers, miR-124-1 was more frequently hypermethylated in NHL, and hence warrants further study. &#169; 2011 Wong et al.</description.abstract>
<language>eng</language>
<publisher>Public Library of Science. The Journal&apos;s web site is located at http://www.plosone.org/home.action</publisher>
<relation.ispartof>PLoS ONE</relation.ispartof>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject.mesh>Epigenesis, Genetic - genetics</subject.mesh>
<subject.mesh>Hematologic Neoplasms - genetics</subject.mesh>
<subject.mesh>Leukemia, Lymphocytic, Chronic, B-Cell - genetics</subject.mesh>
<subject.mesh>Lymphoma - genetics</subject.mesh>
<subject.mesh>MicroRNAs - genetics</subject.mesh>
<title>Epigenetic inactivation of the miR-124-1 in haematological malignancies</title>
<type>Article</type>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1371/journal.pone.0019027</identifier.doi>
<identifier.pmid>21544199</identifier.pmid>
<identifier.pmcid>PMC3081325</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-79955526497</identifier.scopus>
<identifier.hkuros>189637</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-79955526497&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>6</identifier.volume>
<identifier.issue>4</identifier.issue>
<identifier.spage>e19027</identifier.spage>
<identifier.epage>e19027</identifier.epage>
<identifier.eissn>1932-6203</identifier.eissn>
<identifier.isi>WOS:000290015800033</identifier.isi>
<publisher.place>United States</publisher.place>
<identifier.citeulike>9257474</identifier.citeulike>
<bitstream.url>http://hub.hku.hk/bitstream/10722/137369/1/pone.0019027.pdf</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Princess Margaret Hospital Hong Kong